PT  - JOURNAL ARTICLE
AU  - Rangwala, Shamina M.
AU  - Lazar, Mitchell A.
TI  - The Dawn of the SPPARMs?
AID  - 10.1126/stke.2002.121.pe9
DP  - 2002 Feb 26
TA  - Science's STKE
PG  - pe9--pe9
VI  - 2002
IP  - 121
4099  - http://stke.sciencemag.org/content/2002/121/pe9.short
4100  - http://stke.sciencemag.org/content/2002/121/pe9.full
SO  - Sci. STKE2002 Feb 26; 2002
AB  - Thiazolidinediones (TZDs) are used as antidiabetic agents in the treatment of type II diabetes. These compounds are ligands for the nuclear hormone receptor PPARγ, which is highly expressed in adipose tissue. PPARγ acts as a molecular switch in the process of fat cell development. The quest for the ideal antidiabetic agent is challenged by the need to develop PPARγ ligands that improve insulin sensitivity, but do not promote fat cell formation. A newly described PPARγ ligand may represent an initial step in this direction and could lead to improved agents for treating insulin resistance in type II diabetes.